• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童骨髓增殖性疾病

Myeloproliferative diseases in childhood.

作者信息

Nix W L, Fernbach D J

出版信息

Am J Pediatr Hematol Oncol. 1981 Winter;3(4):397-407.

PMID:6174053
Abstract

The experience with myeloproliferative diseases (MPD) in children of a large pediatric hematology-oncology service during a 20-year period is reviewed. Twenty-seven patients with myeloproliferative diseases were treated, six with the juvenile type of chronic myelogenous leukemia (CML), 10 with the adult type of CML, three with familial MPD, one with unclassifiable MPD, and seven with acute leukemia in whom myelofibrosis was either a prodromal or terminal event. The literature is reviewed with particular emphasis regarding the relationships between the juvenile type of CML and monocytic leukemia, the adult type of CML and acute nonlymphocytic leukemia, and the relationship of myelofibrosis and myeloid metaplasia to the acute leukemias. New therapeutic approaches are needed in this heterogenous but interrelated group of disorders.

摘要

回顾了一家大型儿科血液肿瘤中心在20年期间儿童骨髓增殖性疾病(MPD)的治疗经验。共治疗了27例骨髓增殖性疾病患儿,其中6例为幼年型慢性粒细胞白血病(CML),10例为成人型CML,3例为家族性MPD,1例为无法分类的MPD,7例为急性白血病,骨髓纤维化在其中为前驱或终末事件。对相关文献进行了综述,特别强调了幼年型CML与单核细胞白血病、成人型CML与急性非淋巴细胞白血病之间的关系,以及骨髓纤维化和髓外化生与急性白血病的关系。在这组异质性但相互关联的疾病中需要新的治疗方法。

相似文献

1
Myeloproliferative diseases in childhood.儿童骨髓增殖性疾病
Am J Pediatr Hematol Oncol. 1981 Winter;3(4):397-407.
2
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.甲磺酸伊马替尼治疗难治性或复发性急性髓系白血病、高危骨髓增生异常综合征和骨髓增殖性疾病患者的结果。
Cancer. 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416.
3
[Diagnostic and pathogenetic significance of some cytogenetic and cythochemical findings (leukocyte alkaline phosphatase) in systemic hemopathies with myeloproliferative tendencies].
Haematologica. 1970;55(5):311-32.
4
Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders.是慢性特发性骨髓纤维化、伴有髓外化生的骨髓纤维化、慢性巨核细胞 - 粒细胞性骨髓增殖症,还是慢性巨核细胞白血病?关于克隆性髓系疾病分类学的进一步思考。
Leukemia. 2005 Jul;19(7):1139-41. doi: 10.1038/sj.leu.2403804.
5
[Significance of cytogenetic methods in the diagnosis and differential diagnosis of myeloproliferative diseases (review of the literature and personal data)].[细胞遗传学方法在骨髓增殖性疾病诊断及鉴别诊断中的意义(文献综述与个人资料)]
Probl Gematol Pereliv Krovi. 1970 Aug;15(8):53-8.
6
[Metamorphosis of chronic myeloproliferative diseases].[慢性骨髓增殖性疾病的蜕变]
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1983 May-Jun;35(3):223-32.
7
Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.组织病理学在急性髓系白血病、骨髓增生异常综合征及骨髓增生异常/骨髓增殖性疾病的诊断与分类中的应用
Pathobiology. 2007;74(2):97-114. doi: 10.1159/000101709.
8
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.单独使用羟基脲治疗或在白消安治疗后使用羟基脲治疗的费城染色体阴性慢性骨髓增殖性疾病患者中的急性白血病和骨髓增生异常综合征
Am J Hematol. 2003 Sep;74(1):26-31. doi: 10.1002/ajh.10375.
9
[Diagnostic difficulties in osteomyelosclerosis with myeloid metaplasia in relation to the other components of the myeloproliferative syndrome].
Med Interna (Bucur). 1973 Mar;25(3):363-76.
10
Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.两种小儿骨髓增生异常和骨髓增殖性疾病新分类的比较
Pediatr Blood Cancer. 2005 Mar;44(3):240-4. doi: 10.1002/pbc.20174.